Bank of America’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-1,070
| Closed | -$21.7K | – | 8585 |
|
|
2022
Q4 | $21.7K | Buy |
+1,070
| New | +$16.4K | ﹤0.01% | 6713 |
|
|
2022
Q3 | – | Sell |
-384
| Closed | -$5K | – | 8425 |
|
|
2022
Q2 | $5K | Buy |
384
+132
| +52% | +$2.13K | ﹤0.01% | 7615 |
|
|
2022
Q1 | $5K | Hold |
252
| – | – | ﹤0.01% | 7915 |
|
|
2021
Q4 | $8K | Sell |
252
-13
| -5% | -$362 | ﹤0.01% | 7753 |
|
|
2021
Q3 | $6K | Buy |
265
+13
| +5% | +$232 | ﹤0.01% | 7713 |
|
|
2021
Q2 | $3K | Sell |
252
-1,185
| -82% | -$14.6K | ﹤0.01% | 7516 |
|
|
2021
Q1 | $15K | Buy |
+1,437
| New | +$16.4K | ﹤0.01% | 6945 |
|
|
2020
Q2 | – | Sell |
-376
| Closed | -$4K | – | 7246 |
|
|
2020
Q1 | $4K | Sell |
376
-99
| -21% | -$1.19K | ﹤0.01% | 6555 |
|
|
2019
Q4 | $7K | Sell |
475
-186
| -28% | -$2.71K | ﹤0.01% | 6720 |
|
|
2019
Q3 | $10K | Buy |
661
+186
| +39% | +$2.59K | ﹤0.01% | 6727 |
|
|
2019
Q2 | $6K | Hold |
475
| – | – | ﹤0.01% | 6829 |
|
|
2019
Q1 | $6K | Buy |
475
+375
| +375% | +$5.47K | ﹤0.01% | 6774 |
|
|
2018
Q4 | $1K | Hold |
100
| – | – | ﹤0.01% | 7018 |
|
|
2018
Q3 | $2K | Hold |
100
| – | – | ﹤0.01% | 7061 |
|
|
2018
Q2 | $1K | Buy |
+100
| New | +$1.76K | ﹤0.01% | 7011 |
|
|
2017
Q4 | – | Sell |
-1,000
| Closed | -$37K | – | 7341 |
|
|
2017
Q3 | $37K | Buy |
+1,000
| New | +$37.3K | ﹤0.01% | 6062 |
|
Bank of America's OPNT Position: Q1 2023 in Review
Bank of America sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q1 2023, closing a stake of 1,070 shares — an estimated $21.7K sold.
Bank of America first reported a position in OPNT in Q3 2017 and held it in 16 quarters. The position peaked at $37K in Q3 2017. 0 funds tracked by Wall St. Rank hold OPNT as of Q1 2023.
- Bank of America reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
- Bank of America sold 1,070 Opiant Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $21.7K.
- Bank of America first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 16 quarters.
- Bank of America's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $37K in Q3 2017.
- 0 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q1 2023.
Based on Bank of America's 13F filing for Q1 2023, filed 12 May 2023.